Ekso Bionics® Announces Collaboration with Kindred Healthcare to Pilot EksoNR in Long-Term Acute Care Hospitals
February 25 2020 - 8:00AM
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), a leading developer of
exoskeletons for medical and industrial use, today announced a
collaboration with Kindred Healthcare, LLC ("Kindred") to pilot
EksoNR— the most clinically used robotic exoskeleton, in their
long-term acute care hospitals.
Kindred already offers exoskeleton-assisted rehabilitation with
the device in over 20 of its freestanding inpatient Kindred
rehabilitation hospitals. Kindred is the first network to explore
the benefits of EksoNR in the long-term acute care setting. The
pilot began last year and is now being conducted in four of
Kindred’s long-term acute care hospitals in the Houston-metro
area.
“Incorporating the latest exoskeleton technology
into our long-term acute care hospitals is another example of
Kindred’s leadership in using technology to improve patient care,”
said Pete Kalmey, President of Kindred Healthcare’s Hospital
Division. “The advancements EksoNR offers will help us get our
patients up and moving earlier in the recovery process, when they
are at their weakest. We believe the use of this technology will
improve patient outcomes and satisfaction and boost patient morale
at a time when they need it the most.”
EksoNR, the most clinically used robotic
exoskeleton, is an intuitive exoskeleton device that empowers
patients recovering from stroke or other conditions to learn to
walk again with a more natural gait. EksoNR is designed to help
patients get back on their feet by supporting re-learning of
correct step patterns, weight shifting, and potentially mitigating
compensatory behaviors, enabling patients to mobilize earlier and
restore independence.
“Patient access to our technology continues to
steadily grow,” said Jack Peurach, CEO and President of Ekso
Bionics. “Our customers, like Kindred, are at the forefront of
expanding accessibility in various clinical settings to improve
patient outcomes and change the standard of care.”
To find a location with EksoNR near you, visit
eksobionics.com/centers.
About Kindred HealthcareKindred Healthcare, LLC
is a healthcare services company based in Louisville, Kentucky with
annual revenues of approximately $3.2 billion. At December 31,
2019, Kindred through its subsidiaries had approximately 33,000
employees providing healthcare services in 1,678 locations in 46
states, including 71 long-term acute care hospitals, 21 inpatient
rehabilitation hospitals, 10 sub-acute units, 95 inpatient
rehabilitation units (hospital-based) and contract rehabilitation
service businesses which served 1,481 non-affiliated sites of
service. Ranked as one of Fortune magazine’s Most Admired
Healthcare Companies for nine years, Kindred’s mission is to help
our patients reach their highest potential for health and healing
with intensive medical and rehabilitative care through a
compassionate patient experience. For more information, go
towww.kindredhealthcare.com. You can also follow us
on Facebook, LinkedIn, and Twitter.
About Ekso Bionics® Ekso Bionics® is
a leading developer of exoskeleton solutions that amplify human
potential by supporting or enhancing strength, endurance and
mobility across medical and industrial applications. Founded in
2005, the Company continues to build upon its industry-leading
expertise to design some of the most cutting-edge, innovative
wearable robots available on the market. Ekso Bionics is the only
exoskeleton company to offer technologies that range from helping
those with paralysis to stand up and walk, to enhancing human
capabilities on job sites across the globe. The Company is
headquartered in the San Francisco Bay Area and is listed on the
Nasdaq Capital Market under the symbol “EKSO.” For more
information, visit: www.eksobionics.com or
follow @EksoBionics on Twitter.
Forward-Looking StatementsAny statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements. Forward-looking
statements may include, without limitation, statements regarding
(i) the potential benefits of the Company’s products, including the
EksoNR, (ii) the performance or effectiveness of the Company’s
products, including the EksoNR, and (iii) the assumptions
underlying or relating to any statement described in clauses (i)
and (ii) above. Such forward-looking statements are not meant to
predict or guarantee actual results, performance, events or
circumstances and may not be realized because they are based upon
the Company’s current projections, plans, objectives, beliefs,
expectations, estimates and assumptions and are subject to a number
of risks and uncertainties and other influences, many of which the
Company has no control over. Actual results and the timing of
certain events and circumstances may differ materially from those
described by the forward-looking statements as a result of these
risks and uncertainties. Factors that may influence or contribute
to the inaccuracy of the forward-looking statements or cause actual
results to differ materially from expected or desired results may
include, without limitation, the Company’s inability to obtain
adequate financing to fund the Company’s operations and necessary
to develop or enhance the Company’s technology, the significant
length of time and resources associated with the development of the
Company’s products, the Company’s failure to achieve broad market
acceptance of the Company’s products, the failure of the Company’s
sales and marketing efforts or of partners to market the Company’s
products effectively, adverse results in future clinical studies of
the Company’s medical device products, the failure to obtain or
maintain patent protection for the Company’s technology, the
failure of the Company to obtain or maintain regulatory approval to
market the Company’s medical devices, the lack of product
diversification, existing or increased competition, and the
Company’s failure to implement the Company’s business plans or
strategies. These and other factors are identified and described in
more detail in the Company’s filings with the U.S. Securities and
Exchange Commission. To learn more about Ekso Bionics please visit
the Company’s website at www.eksobionics.com or follow @EksoBionics
on Twitter. The Company does not undertake to update these
forward-looking statements.
Media Contact:Carrie Yamond
Mas917-371-2320cmas@eksobionics.com
Investor Contact:David
Carey212-867-1768investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2023 to Apr 2024